In 2021, we conducted a study to determine the effectiveness of seasonal malaria chemoprevention (SMC) in terms of reduction in incidence of malaria infection among children under five. In the intervention arm, 90 percent of children never experienced a malaria episode, compared with 15 percent in the control arm. The following year, we carried out a three-arm cluster randomised controlled trial (cRCT) to assess the effectiveness of SPAQ in children 3–59 months and DP in children 6–59 months, respectively. The malaria incidence rate was 1 per 100 person-months in the intervention arm and 20 per 100 person-months in the control arm.
This oral presentation was given at the Multilateral Initiative on Malaria (MIM) Society's 8th Pan-African Malaria Conference.
« Back to Publications